NVO logo

NVO
Novo Nordisk A/S

28,458
Mkt Cap
$176.48B
Volume
30.02M
52W High
$93.80
52W Low
$43.08
PE Ratio
15.24
NVO Fundamentals
Price
$55.11
Prev Close
$52.39
Open
$53.92
50D MA
$49.24
Beta
0.73
Avg. Volume
15.9M
EPS (Annual)
$3.29
P/B
8.70
Rev/Employee
$551,951.47
Loading...
Loading...
News
all
press releases
Promising Pharmaceutical Stocks To Follow Now - January 5th
Eli Lilly and Company, Novo Nordisk A/S, and AbbVie are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly...
MarketBeat·6h ago
News Placeholder
More News
News Placeholder
Best Medical Stocks To Follow Now - January 5th
Eli Lilly and Company, UnitedHealth Group, Novo Nordisk A/S, Johnson & Johnson, Thermo Fisher Scientific, AbbVie, and Pfizer are the seven Medical stocks to watch today, according to MarketBeat's...
MarketBeat·6h ago
News Placeholder
Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost
Novo Nordisk launches Wegovy weight loss pill in the US, showing up to 17% weight loss, with prices starting near $5 a day and broad pharmacy and telehealth access.read more...
Benzinga·8h ago
News Placeholder
LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?
LLY has surged 28% in three months, driven by blockbuster GLP-1 drugs, its $1T market cap and a deep obesity pipeline.
Zacks·10h ago
News Placeholder
LifeMD Adds Novo Nordisk's Weight-loss Pill Wegovy To Telehealth Platform
(RTTNews) - LifeMD, Inc. (LFMD), a provider of virtual primary care and pharmacy services, on Monday said it is now offering Novo Nordisk's Wegovy pill for chronic weight management and...
Nasdaq News: Markets·11h ago
News Placeholder
Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?
Novo Nordisk's FDA-approved Wegovy pill marks the first oral GLP-1 weight loss therapy, aiming to revive momentum and reshape competition in 2026.
Zacks·12h ago
News Placeholder
Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America
Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in...
PR Newswire·12h ago
News Placeholder
First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
The drug's cash prices are among the lowest on the market, ranging from $149 to $299 per month, depending on the dose...
CNBC: Top News·12h ago
News Placeholder
Novo Nordisk Offers Oral Wegovy Pill At $149 A Month Following FDA’s Approval In December: Retail Tells Shorts ‘It’s Time To Give Up’
The 1.5 mg and 4 mg doses of Wegovy will be available to self-paying customers at these prices beginning January 5.
Stocktwits·13h ago
News Placeholder
Novo Nordisk A/S $NVO Position Increased by Allen Wealth Management LLC
Allen Wealth Management LLC lifted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 960.2% during the third quarter, according to the company in its most recent filing with the SEC. The...
MarketBeat·16h ago
<
1
2
...
>

Latest NVO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.